Portfolio news 2010
Pharminox Ltd – Appoints Iain Ross as Chairman
08 Jan 2010
Pharminox Limited, ("Pharminox" or "the Company") the UK-based
cancer drug discovery and development company, today announced that
it has appointed Iain Ross as Non-executive Chairman. Mr Ross takes
over from Dr Mario Polywka, who is stepping down as Chairman due to
other commitments, but will remain on the Baord in a non-executive
Mr Ross is currently Non-executive Chairman of Silence
Therapeutics plc, the UK-quoted biotechnology company (AIM:SLN)
which recently merged with the US company Intradigm Corporation. He
also holds non-executive directorships with a number of other
companies in the sector.
Commenting on today's announcement, Peter Worrall, Chief
Executive of Pharminox, said, "The appointment of Iain
Ross is an important milestone in the strategic development of
Pharminox. Iain brings a wealth of experience and an impressive
track record of fund raising and shareholder value generation in
the biotechnology sector and will greatly strengthen the Board at
this important stage in the Company's development.
"I would also like to take this opportunity to thank Mario
Polywka for the tremendous contribution he has made as Chairman of
the Board over the last five years. I am very pleased that Mario
has agreed to remain on the Board as a non-executive director."
Iain Ross commented, "I am delighted to be joining the board of
Pharminox. The Company is at an exciting stage and I have been very
impressed both by the calibre of the people and the quality of the
science. I look forward to working with the Board and Management
Team to create real and sustainable shareholder value."